Mounjaro, Ozempic and Wegovy are available as weekly subcutaneous injections that can be self-administered. Ozempic, Rybelsus and Wegovy are offered as daily oral tablets. The approved uses and dosage forms vary depending on the brand.
Semaglutide reduced A1C levels by approximately 1% to 2% while tirzepatide lowered A1C by 2% to 2.5% in studies comparing treatments for type 2 diabetes. Patients taking tirzepatide lost an average of 50.3 lbs (22.9 kg) compared to 33.1 lbs with semaglutide in a head-to-head comparison for weight loss. Individual responses can vary while tirzepatide may provide greater weight loss and slightly stronger blood sugar control compared to semaglutide. Higher doses of tirzepatide may also lead to more gastrointestinal side effects.
Recent price reductions have made these medications more accessible whether paying out-of-pocket or through prescription insurance.
Key Takeaways
- Tirzepatide and semaglutide are prescription GLP-1 receptor agonists used alongside diet and exercise to treat type 2 diabetes or to support weight loss and weight management.
- These medications are available under different brand names. Semaglutide is sold as Ozempic, Rybelsus, or Wegovy while tirzepatide is marketed as Mounjaro or Zepbound. Some brands may also be approved for additional uses such as reducing cardiovascular risk, managing obstructive sleep apnea or supporting kidney or liver health.
- Each brand differs in approved uses, dosage forms, strengths, and cost Therefore you should discuss options with your medical professional before starting treatment.
- Wegovy which include semaglutide as active ingredient is FDA-approved for adolescents aged 12 and older for weight loss and management while Mounjaro which includes tirzepatide as the active ingredient is approved for children 10 and older with type 2 diabetes.
What is GLP-1 and How Does it Help with Weight Loss?
Semaglutide comes under Ozempic, Wegovy, Rybelsus and tirzepatide available as Mounjaro, Zepbound are both incretin mimetics medications that mimic natural gut hormones. But they differ slightly in how they work and are dosed. Both are FDA-approved under various brand names for type 2 diabetes and long-term weight management.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist mimicking the body’s natural GLP-1 hormone by binding to its receptor. Tirzepatide is a dual acting receptor agonist that targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is also a natural incretin hormone same as GLP-1 which may enhance tirzepatide’s effects.
These medications work by stimulating insulin release from the pancreas when needed to help lower blood sugar, reducing sugar production by the liver through suppression of glucagon and slowing gastric emptying which helps you feel fuller longer, reduces appetite and can lead to weight loss.
These drugs should not be used together or with any other GLP-1 or GIP receptor agonists. Mounjaro, Wegovy, Ozempic, and Zepbound are administered once weekly as subcutaneous injections in the abdomen, thigh or upper arm. You or a caregiver can be trained to give these injections at home using an injector pen.
Which GLP-1 Drug is Best for Weight Loss?
Patients taking tirzepatide lost an average of 50.3 lbs (22.9 kg) compared to 33.1 lbs with semaglutide in head-to-head weight loss comparisons.
Tirzepatide may provide greater weight loss and stronger blood sugar reduction, although individual results can vary. Higher doses of tirzepatide may also cause more gastrointestinal side effects.
Semaglutide has been shown to lower cardiovascular risks including heart attack, stroke, and heart-related death in patients with type 2 diabetes or obesity who have established heart disease. Both semaglutide products are FDA-approved for this use while cardiovascular outcomes studies for tirzepatide are still ongoing.
A U.S. study using a cost-per-treatment analysis suggested that tirzepatide may provide better value for weight loss compared to semaglutide over 68 to 72 weeks. Tirzepatide at 10 mg or 15 mg reduced body weight more effectively than semaglutide at 1 mg or 2 mg. Tirzepatide at 5 mg was more effective than semaglutide at 0.5 mg or 1 mg.
Best GLP-1 Pills for Weight Loss (Oral Options)
Wegovy Pill (Oral Semaglutide) – First FDA- Approved GLP-1 Pill for Weight Loss
The Wegovy pill provides an alternative to the injectable Wegovy providing similar benefits for weight management, blood sugar control, cholesterol and cardiovascular risk. The pill is taken by mouth and does not require refrigeration making it a convenient option for those who prefer to avoid needles or have storage limitations.
Wegovy pills should be taken only after a thorough medical evaluation and as part of a comprehensive plan that includes healthy eating, regular exercise, and ongoing follow-up with a healthcare provider. The effectiveness of the Wegovy pill depends on proper administration. The pill has a special coating and must be taken exactly as directed to work as intended. First thing in the morning on an empty stomach after an overnight fast with no more than 4 ounces of water and without eating, drinking, or taking other medications for at least 30 minutes. This strict routine may present a challenge for patients taking multiple medications.
Switching to the pill should be discussed with a healthcare provider for those currently using the injectable Wegovy. Some may prefer the convenience of a once-weekly injection while others may find that a daily pill fits better into their lifestyle.
Orforglipron – Investigational Oral GLP-1 Weight Loss Pill
Orforglipron is an investigational, once-daily oral GLP-1 receptor agonist currently being studied for the treatment of type 2 diabetes and obesity. Designed to help lower blood sugar and promote weight loss. It is available in pill form. Orforglipron could be taken without any restrictions on food or water timing in clinical trials.
Orforglipron is currently being studied in clinical trials by Lilly to assess its safety and effectiveness for weight loss and type 2 diabetes. Early results have been promising with additional data expected in the first quarter of 2026. The medication has not yet been approved for use. Lilly submitted orforglipron for regulatory review as a treatment for overweight and obesity in 2025 and plans to seek approval for type 2 diabetes in 2026.
Oral GLP-1 Pills vs. Injections: Which Works Better?
GLP-1 medications such as semaglutide work the same way in the body whether taken as a pill or injection. They mimic a natural hormone that helps regulate appetite, blood sugar, and feelings of fullness. The main difference lies in how the body absorbs them.
GLP-1 injections including Wegovy are about 90% bioavailable (the portion of the drug your body can absorb and use), taken once weekly and absorption is consistent and predictable.
GLP-1 pills such as oral semaglutide are only 1–2% bioavailable. It is taken daily and absorption can vary between individuals.
Your body absorbs much less of the GLP-1 drug in pill form compared to injections even if the oral dose seems higher on paper.
Ozempic vs Wegovy: Same Drug, Different Purpose
Ozempic and Wegovy both contain semaglutide and work as GLP-1 receptor agonists. But they have different FDA-approved uses. Only Wegovy is specifically approved for chronic weight management while both can lead to weight loss.
Ozempic (semaglutide injection or tablet) is FDA-approved for adults with type 2 diabetes to improve blood sugar control, alongside diet and exercise, reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease and reduce the risk of kidney disease progression, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease with only injection. Ozempic is not FDA-approved for weight loss although many patients lose weight while using it and some clinicians prescribe it off-label for this purpose.
Wegovy (semaglutide injection) is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight related condition such as high blood pressure, type 2 diabetes and high cholesterol, children 12 years and older with obesity based on age and sex-specific BMI cutoffs, reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and overweight or obesity and treatment of non cirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults.
Wegovy (semaglutide tablets) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition and reducing cardiovascular risk in adults with cardiovascular disease and overweight or obesity. Wegovy must be used along with a reduced calorie diet and increased physical activity.
How does semaglutide work?
Semaglutide increases insulin release when blood sugar is high and reduces sugar production by the liver improving blood sugar control in type 2 diabetes and slows gastric emptying and signals fullness in the brain reducing appetite and calorie intake.
Weight Loss Differences between Ozempic and Wegovy
Both Ozempic and Wegovy share the same active ingredient and side effect profile. Higher doses of semaglutide result in greater weight loss. Wegovy injections are typically prescribed at higher doses than Ozempic which may lead to more significant weight loss. Studies with Wegovy show adults lost around 15% of body weight over 68 weeks on the 2.4 mg dose and up to 21% with the 7.2 mg dose in the STEP UP study over 72 weeks. Adults lost about 14 lb (6.4 kg) over 40 weeks using the 2 mg weekly dose for type 2 diabetes with Ozempic and it also led to more weight loss compared to other type 2 diabetes treatments like Bydureon (exenatide), Januvia (sitagliptin), and Trulicity (dulaglutide).
Wegovy is designed specifically for long-term weight management and its higher dosing options may produce greater weight loss than Ozempic while both medications improve blood sugar and can support weight loss.
Moujaro vs Zepbound: Why is Tirzepatide Stronger?
Tirzepatide is a powerful medication because it activates two gut hormone receptors which are GIP and GLP-1 to help manage blood sugar and support weight loss. Its actions include stimulating insulin release when blood glucose is high, slowing gastric emptying which increases feelings of fullness and helps control post-meal sugar spikes reducing glucagon production from the liver, improving insulin sensitivity and suppressing appetite through effects on the central nervous system.
Mounjaro is primarily used to treat type 2 diabetes in adults. This should be taken alongside diet and exercise and helps improve blood sugar control.
Zepbound is primarily used for chronic weight management in adults with obesity (BMI ≥30 kg/m²), overweight (BMI ≥27 kg/m²) and at least one weight-related condition such as high blood pressure, dyslipidemia and sleep apnea. This drug is used in combination with a reduced-calorie diet and increased physical activity. This is also used to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
- Key points:Both contain the same active ingredient (tirzepatide) and work the same way in the body.
- Clinical trials showing an average 20.9% weight loss apply to both Mounjaro and Zepbound.
- Choosing between them depends on the patient’s primary medical condition such as diabetes vs. weight management, insurance coverage, cost considerations and medical professional’s preference
Semaglutide vs Tirzepatide
The main difference between these drugs is how they work. Tirzepatide acts on both GLP-1 and GIP receptors improving insulin sensitivity, increasing the fat metabolism and satiety more effectively. Therefore, tirzepatide has the effect on both type 2 diabetes and weight loss. Semaglutide acts only on GLP-1 receptors increasing the insulin secretion while reducing the glucagon release. This active ingredient slows down gastric emptying and promotes satiety. Therefore, tirzepatide has dual hormone action while semaglutide has single hormone action. Clinical researchers suggest that this dual mechanism of tirzepatide is the key reason for its higher demand than semaglutide.
How I Reviewed GLP-1 Medications for Weight Loss?
Weight Loss Effectiveness
Medical practitioners prescribe these medications for weight loss which is one of the most important reasons for their demand. Tirzepatide showed weight loss up to 20% or more as an average while semaglutide showed loss of body weight between 14% to 15 % within 68 weeks. According to these clinical results, tirzepatide produced greater weight loss than semaglutide because of the added activity of tirzepatide on GIP hormone. This increases fat metabolism, improves appetite regulation and supports greater energy balance control.
Side Effects and Tolerability
Both medications share similar side effects because they affect the gut-brain axis. Common side effects of both tirzepatide and semaglutide are nausea, vomiting, diarrhea and constipation. These symptoms range from mild to moderate and occur during dose escalation.
Tirzepatide may cause slightly fewer gastrointestinal side effects than semaglutide. The GI symptoms increase with the increase of the tirzepatide dose.
Safety and FDA Approval
Tirzepatide is FDA approved for both type 2 diabetes and obesity while Semaglutide is FDA approved for type 2 diabetes. But, both are now widely used for weight loss even in non diabetic individuals.
Dosing Frequency and Convenience
Tirzepatide is administered as a weekly injection with a dose range from 5 mg to 15 mg. Semaglutide is also administered as a weekly injection but up to 2.4 mg.
Cost and Availability
Tirzepatide is new and may be more expensive and less accessible in some regions while Semaglutide is generally more widely available globally although pricing varies by country and insurance plan. The demand for each drug influences the choice between two drugs.
Which GLP-1 Is FDA Approved for Weight Loss?
FDA has approved Wegovy which includes semaglutide as the active ingredient, Zepbound which include tirzepatide as active ingredient and Saxenda which include liraglutide as active ingredient for weight loss. Licensed medical professionals should prescribe these drugs because these drugs are known as prescription medications. You should choose legitimate GLP-1 providers that follow FDA and valid telehealth guidance such as Healify Clinic.
Tirzepatide:
Tirzepatide is a once-weekly injectable medication available as Zepbound and Mounjaro. Zepbound is FDA approved for weight management and Mounjaro is FDA approved for type 2 diabetes. This is used to regulate blood sugar levels while losing weight. Tirzepatide acts on two hormones that affect appetite and glucose metabolism. These hormones are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) respectively that are produced naturally in the body. The medication mimics these hormones as a GLP-1 and GIP receptor agonist.
This medication has become unique due to its ability to target two hormones. Tirzepatide can mimic the effect of both GLP-1 and GIP hormones and results in a combined effect in your body. It slows the digestion and decreases the appetite helping you to eat less and lose weight. This medication also increases the production of insulin by stimulating the pancreas when you eat, managing blood sugar levels effectively.
Semaglutide:
Semaglutide is a GLP-1 receptor agonist that mimics the GLP-1 hormone. This is available under brand names Ozempic for type 2 diabetes and Wegovy for weight loss. Both drugs are administered as once weekly injections and are approved for managing type 2 diabetes with additional use for obesity treatment.
Liraglutide:
Liraglutide is an older medication which has FDA approval for weight loss and sold under the brand name Saxenda. Patients should take this as a daily injection unlike new GLP-1 drugs that use weekly dosing. Medical practitioners prescribe this less often compared to new drugs because patients prefer once weekly injectable drugs over daily injectable drugs.
GLP-1 Microdosing for Weight Loss – Does it Work?
Microdosing GLP-1 medications is taking smaller doses than the standard amounts recommended by the manufacturer. People may try microdosing for different reasons.
Medication shortages because of high demand for GLP-1 drugs has caused supply issues and some users microdose to stretch their supply. This can be concerning as research shows that stopping certain GLP-1 medications often leads to weight regain.
GLP-1 medications are expensive exceeding $1,000 per month without insurance. Some people try microdosing to reduce costs.
Microdosing may still produce benefits for some individuals. There is limited research supporting microdosing and professional organizations such as the American Diabetes Association do not endorse it. Therefore you should always talk to your doctor before changing your dose, considering cost, or experimenting with microdosing, stick to FDA-approved GLP-1 medications whenever possible as these come in injectable pens with precise dosing. Compounded GLP-1 drugs, often used for microdosing, come in vials and syringes which allow dose flexibility but increase the risk of taking too much or too little. The contents of these vials are not FDA-evaluated. Therefore, their safety and effectiveness are not guaranteed.
Microdosing carries risks and lacks strong clinical evidence while it may work for some people. Proper dosing under medical supervision remains the safest approach.
Are GLP-1 Medications Safe for Weight Loss?
GLP-1 medications are considered safe for weight loss with the prescription of a licensed doctor. Most of the medical guidelines support GLP-1 medications as an effective option for weight loss and obesity.
